Mesentech is a clinical stage biotech developing therapies for musculoskeletal disease. MES1022, currently in phase 1, is a potent anabolic that increases muscle mass and reduces fibrosis stemming from muscular dystrophy. MES3015 is a novel systemically administered anti-cancer therapy that selectively distributes to bone; it is being developed to treat metastases to bone and osteosarcomas.